ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer.Journal of Taibah University Medical Sciences · 2026Article
- β-Caryophyllene protects male fertility and testicular function against paclitaxel-induced damage in a murine model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Predicting taxane-induced peripheral neuropathy by nailfold capillaroscopy: The CAPNEU pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- SIVA1 Knockdown Drives Aggressive Phenotypes in Triple-Negative Breast Cancer Cells while Enhancing Paclitaxel Efficacy.ACS omega · 2026Article
- QSAR Modeling for Predicting ICInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Paclitaxel (PTX), a member of the taxane family of anticancer drugs, is considered one of the most effective chemotherapeutic agents used worldwide. It is widely used in the treatment of solid tumors, including non-small-cell lung, colon, breast, ovarian, prostate, and bladder cancers. Its anticancer activity involves multiple mechanisms: mitotic arrest, mitochondrial damage, and apoptosis induction. Hence, being a non-targeted drug, PTX is associated with many types of toxicities, limiting its effectiveness and affecting the patient's quality of life. Unfortunately, this may result in treatment modifications or even discontinuation. The common clinical toxicities encountered with PTX include cognitive impairment, peripheral neuropathy, testicular toxicity, pulmonary toxicity, cardiotoxicity, hepatotoxicity, and nephrotoxicity. However, the underlying mechanisms of these toxicities remain elusive. This review article focuses on PTX-induced toxicities and the suggested detailed pathological mechanisms underlying each one.
Indexed as
Identifiers
40864255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.